Evidence map›Paper›PMID 35326403›Full record

ArticleCells2022

Optogenetic Control of Engrafted Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Live Mice: A Proof-of-Concept Study.

Jyotsna Joshi, Bing Xu, Michael Rubart, Yun Chang, Xiaoping Bao, Hari P Chaliki, Luis R Scott, Wuqiang Zhu

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jyotsna JoshiDepartment of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
Bing XuDepartment of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
Michael RubartDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0002-7386-6943
Yun ChangDepartment of Chemical Engineering, Purdue University, West Lafayette, IN 47907, USA.
Xiaoping BaoDepartment of Chemical Engineering, Purdue University, West Lafayette, IN 47907, USA.ORCID 0000-0003-0955-6868
Hari P ChalikiDepartment of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
Luis R ScottDepartment of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
Wuqiang ZhuDepartment of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.ORCID 0000-0001-5217-7789
Mayo Clinic in Arizona · USPurdue University West Lafayette · USIndiana University School of Medicine

Funding

Transcriptional regulation of cardiac morphogenesisP01HL134599 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI Lei Yang · 2017 to 2026
$25.7M
Myocardial Repair with a Novel Engineered Cardiac Muscle PatchR01HL142627 · NHLBI · MAYO CLINIC ARIZONA · PI ZHU, WUQIANG · 2019 to 2022
$1.7M
Cardioprotection and uncoupling myofibroblast-myocyte communicationsR01HL148165 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI CONWAY, SIMON JAMES, RUBART-VAN DER LOHE, MICHAEL · 2019 to 2022
$1.6M
Myocardial Repair with a Novel Engineered Cardiac Muscle PatchR56HL142627 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ZHU, WUQIANG · 2018 to 2018
$371k
American Heart Association 20TPA35490001NHLBI NIH HHS P01 HL134599NHLBI NIH HHS R01 HL142627NHLBI NIH HHS R01 HL148165NHLBI NIH HHS R56 HL142627
6 · The paper itself

Abstract

Background: Cellular transplantation has emerged as promising approach for treating cardiac diseases. However, a poor engraftment rate limits our understanding on how transplanted cardiomyocytes contribute to cardiac function in the recipient’s heart. Methods: The CRISPR/Cas9 technique was employed for stable and constitutive gene expression in human-induced pluripotent stem-cell-derived cardiomyocytes (hiPSC-CMs). Myocardial infarction was induced in adult immunodeficient mice, followed by intramyocardial injection of hiPSC-CMs expressing either CCND2/channelrhodopsin 2 (hiPSC-CCND2OE/ChR2OECMs) or CCND2/luciferase (hiPSC-CCND2OE/LuciOECMs). Six months later, hemodynamics and intramural electrocardiogram were recorded upon blue light illuminations in anesthetized, open-chest mice. Results: Blue light resets automaticity of spontaneously beating hiPSC-CCND2OE/ChR2OECMs in culture, but not that of hiPSC-CCND2OE/LuciOECMs. Response to blue light was also observed in mice carrying large (>106 cells) intracardiac grafts of hiPSC-CCND2OE/ChR2OECM but not in mice carrying hiPSC-CCND2OE/LuciOECMs. The former exhibited single premature ventricular contractions upon light illumination or ventricular quadrigeminy upon second-long illuminations. At the onset of premature ventricular contractions, maximal systolic ventricular pressure decreased while ventricular volume rose concomitantly. Light-induced changes reversed upon resumption of sinus rhythm. Conclusions: We established an in vivo model for optogenetic-based modulation of the excitability of donor cardiomyocytes in a functional, reversible, and localized manner. This approach holds unique value for studying electromechanical coupling and molecular interactions between donor cardiomyocytes and recipient hearts in live animals.

Indexed as

Induced Pluripotent Stem CellsMyocardial InfarctionVentricular Premature ComplexesAnimalsHumansMiceMyocytes, CardiacOptogeneticscardiomyocytescell therapyheart failureoptogeneticsstem cells

Identifiers

PMID35326403
PMCPMC8946017
OpenAlexW4220927088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.